Tonix Pharmaceuticals Presents Data on TNX-801 Mpox Vaccine
Tonix Pharmaceuticals Holding Corp. presented data on TNX-801, a live virus vaccine investigational candidate, at the World Vaccine Congress–Europe 2025.
TNX-801 is designed to provide durable protection against mpox and smallpox, demonstrating favorable safety, immunogenicity, and long-term protection in multiple preclinical models.
- TNX-801 showed favorable safety and immunogenicity.
- Data supports advancement of TNX-801 toward clinical development.
A copy of the Company’s presentation, titled “Safety, Durability and Protection of a Single-Dose TNX-801 Mpox Vaccine,” is available under the Scientific Presentations tab of the Tonix website at www.tonixpharma.com.
Author's summary: Tonix Pharmaceuticals presents data on TNX-801 vaccine.
More News
- The Bucks' first trade candidate is already painfully obvious
- Newsworthy: Jackson Preparatory School
- World’s smallest 'bioprinter' is the size of a pill
- Tipp GAA club to donate lotto earnings to help a family of a club member undergoing treatment
- BURTON HIGH SCHOOL TO CROWN HOMECOMING ROYALTY FRIDAY
- Get a look inside the new juvenile justice center
- Meta to add parental controls for kids' interactions with AI chatbots
- ‘Building community’: Hundreds attend inaugural LIC Wellness Fest – QNS
- ONE to watch Ali Afroogh stays undefeated in his ONE Friday Fights debut via third-round TKO!
- Keanu Reeves Lifts Aziz Ansari's Gentle Comedy Good Fortune